PFS Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

PFS Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$15.1M	Buy	43,011 +150	+0.3%	+$50.5K	0.25%	106
2023 Q1	$13.8M	Buy	42,861 +357	+0.8%	+$107K	0.24%	109
2022 Q4	$12.3M	Sell	42,504 -1,560	-4%	-$475K	0.23%	100
2022 Q3	$12.8M	Sell	44,064 -6,014	-12%	-$1.73M	0.23%	92
2022 Q2	$14.1M	Sell	50,078 -6,813	-12%	-$1.82M	0.28%	97
2022 Q1	$14.8M	Sell	56,891 -11,892	-17%	-$2.82M	0.28%	95
2021 Q4	$15.1M	Buy	68,783 +744	+1%	+$145K	0.29%	95
2021 Q3	$13.1M	Buy	68,039 +1,521	+2%	+$297K	0.27%	93
2021 Q2	$13.2M	Buy	66,518 +7,789	+13%	+$1.63M	0.3%	94
2021 Q1	$12.6M	Buy	58,729 +23,104	+65%	+$5.07M	0.32%	84
2020 Q4	$8.36M	Buy	35,625 +7,426	+26%	+$1.7M	0.23%	105
2020 Q3	$7.67M	Buy	28,199 +3,561	+14%	+$982K	0.25%	89
2020 Q2	$7.15M	Buy	24,638 +8,998	+58%	+$2.44M	0.26%	85
2020 Q1	$3.72M	Buy	15,640 +3,261	+26%	+$748K	0.16%	101
2019 Q4	$2.71M	Buy	12,379 +1,757	+17%	+$356K	0.1%	125
2019 Q3	$1.8M	Buy	10,622 +3,710	+54%	+$656K	0.08%	124
2019 Q2	$1.23M	Buy	6,912 +4,669	+208%	+$816K	0.06%	122
2019 Q1	$413K	Buy	+2,243	New	+$414K	0.02%	125

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PFS Investments's VRTX Position: Q2 2023 in Review

PFS Investments increased its Vertex Pharmaceuticals (VRTX) stake by 0.35% in Q2 2023, buying an estimated $50.5K and bringing the position to 43,011 shares worth $15.1M. The position accounts for 0.25% of the portfolio, ranked #106.

PFS Investments first reported a position in VRTX in Q1 2019 and has held it in 18 quarters since. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

PFS Investments held 43,011 shares of Vertex Pharmaceuticals worth $15.1M as of Q2 2023.
PFS Investments bought 150 Vertex Pharmaceuticals shares in Q2 2023, an estimated $50.5K.
Vertex Pharmaceuticals made up 0.25% of PFS Investments's portfolio in Q2 2023, its #106 holding.
PFS Investments first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 18 quarters since.
1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on PFS Investments's 13F filing for Q2 2023, filed 14 Aug 2023.